Format

Send to

Choose Destination
Antiviral Res. 2014 Apr;104:153-5. doi: 10.1016/j.antiviral.2014.01.012. Epub 2014 Jan 24.

Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.

Author information

1
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, UK. Electronic address: sjsmither@dstl.gov.uk.
2
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, UK.
3
MediVector, Inc., Two International Place, 22nd Floor, Boston, MA 02110, United States.

Abstract

Filoviruses cause disease with high case fatality rates and are considered biological threat agents. Licensed post-exposure therapies that can be administered by the oral route are desired for safe and rapid distribution and uptake in the event of exposure or outbreaks. Favipiravir or T-705 has broad antiviral activity and has already undergone phase II and is undergoing phase III clinical trials for influenza. Here we report the first use of T-705 against Ebola virus. T-705 gave 100% protection against aerosol Ebola virus E718 infection; protection was shown in immune-deficient mice after 14 days of twice-daily dosing. T-705 was also shown to inhibit Ebola virus infection in cell culture. T-705 is likely to be licensed for use against influenza in the near future and could also be used with a new indication for filovirus infection.

KEYWORDS:

Aerosol; Bioterrorism; Broad-spectrum; Ebola; Favipiravir; Licensed

PMID:
24462697
DOI:
10.1016/j.antiviral.2014.01.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center